Coastlands Capital reports acquisition of $309,921.66 in Bolt Biotherapeutics common shares
BOLT•Coastlands Capital, a 10% owner of Bolt Biotherapeutics, acquired 53,094 common shares, bringing its indirect beneficial holdings to 515,510 shares. The purchases were made at $5.89 and $5.7499 per share.
1. Share purchases
Coastlands Capital acquired 53,094 Bolt Biotherapeutics common shares. The purchases comprised 33,094 shares at $5.89 per share and 20,000 shares at $5.7499 per share, bringing Coastlands Capital’s indirect beneficial holdings to 515,510 shares.




